Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Vincent Miller, Daniel Grosu

Premium

Foundation Medicine has appointed Vincent Miller to senior vice president of clinical development, where he will be responsible for driving clinical strategy to support and expand the use of the company's sequencing-based cancer test.

He joins Foundation Medicine from Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University where he served as attending physician and member.

Miller holds a BA from the University of Pennsylvania and an MD from the University of Medicine and Dentistry of New Jersey.


Illumina has named Daniel Grosu as vice president and chief medical officer, a newly created position. In this role, Grosu will help build Illumina's diagnostic capabilities through collaborations with regulatory agencies, internal product development teams, and the company's CLIA-certified clinical laboratory.

Previously, Grosu was group director of clinical science and clinical and medical affairs at Ortho-Clinical Diagnostics. He has also served as director and global clinical leader of global clinical development and diagnostic imaging at Bayer Healthcare. He holds a BS and an MS from Wheaton College, an MD from Saint Louis University, and an MBA from the University of Oxford.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.